447. Reduction of Sensory Reactivity Symptoms Corresponds to Improved Psychiatric Symptoms in an Open-Label Study of Low-Dose Ketamine in Children With ADNP Syndrome

ADNP syndrome is a rare neurodevelopmental disorder caused by de novo mutations in the activity-dependent neuroprotective protein (ADNP) gene and characterized by developmental delay, intellectual disability, and autism features. Preclinical research indicates ketamine displays neuroprotective effects and could aid in increasing production of the ADNP protein. Our group reported nominal improvements in social behavior, hyperactivity, repetitive behaviors, and sensory sensitivities in a pilot open-label clinical trial in ADNP syndrome using a single infusion of low-dose ketamine (0.5mg/kg).